Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 3Genitourinary 3Thoracic 2Gynecologic 2Plasma cell 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 1228Lung Neoplasms 560Colorectal Neoplasms 282Breast Neoplasms 257Neoplasms 254Melanoma 236Small Cell Lung Carcinoma 234Ovarian Neoplasms 234Pancreatic Neoplasms 186Squamous Cell Carcinoma of Head and Neck 171Neoplasm Metastasis 171Carcinoma, Renal Cell 164Stomach Neoplasms 158Triple Negative Breast Neoplasms 127Head and Neck Neoplasms 121Esophageal Neoplasms 115Prostatic Neoplasms 106Urinary Bladder Neoplasms 105Colonic Neoplasms 95Uterine Cervical Neoplasms 93Endometrial Neoplasms 93Mesothelioma 84Mesothelioma, Malignant 79Carcinoma, Hepatocellular 78Sarcoma 70Carcinoma, Transitional Cell 69Kidney Neoplasms 65Carcinoma, Ovarian Epithelial 50Adenocarcinoma of Lung 47Rectal Neoplasms 45

Interventions

pembrolizumab 1durvalumab 1atezolizumab 1Etoposide 1Carboplatin 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Bites and Stings × Thoracic × Clear all
NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Amgen

Phase 1 Active not recruiting
184 enrolled
Thoracic

Bites and Stings, Lung Neoplasms

NCT03319940 2025-11-19

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Amgen

Phase 1 Active not recruiting
269 enrolled
Thoracic

Bites and Stings, Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡